X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs BIOCON LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS BIOCON LTD IPCA LABS/
BIOCON LTD
 
P/E (TTM) x 28.0 36.6 76.5% View Chart
P/BV x 2.1 4.9 44.1% View Chart
Dividend Yield % 0.2 1.5 15.7%  

Financials

 IPCA LABS   BIOCON LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
BIOCON LTD
Mar-16
IPCA LABS/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs643496 129.7%   
Low Rs503397 126.8%   
Sales per share (Unadj.) Rs254.4174.3 146.0%  
Earnings per share (Unadj.) Rs16.144.8 35.9%  
Cash flow per share (Unadj.) Rs29.856.9 52.3%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.21.1 15.6%  
Book value per share (Unadj.) Rs194.6202.8 95.9%  
Shares outstanding (eoy) m126.20200.00 63.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.6 88.0%   
Avg P/E ratio x35.710.0 358.1%  
P/CF ratio (eoy) x19.27.8 245.5%  
Price / Book Value ratio x2.92.2 133.9%  
Dividend payout %6.211.2 55.8%   
Avg Mkt Cap Rs m72,30089,220 81.0%   
No. of employees `00013.34.4 301.3%   
Total wages/salary Rs m6,9606,363 109.4%   
Avg. sales/employee Rs Th2,413.57,894.5 30.6%   
Avg. wages/employee Rs Th523.21,441.2 36.3%   
Avg. net profit/employee Rs Th152.42,029.7 7.5%   
INCOME DATA
Net Sales Rs m32,10634,854 92.1%  
Other income Rs m226845 26.7%   
Total revenues Rs m32,33235,699 90.6%   
Gross profit Rs m4,4488,200 54.2%  
Depreciation Rs m1,7302,423 71.4%   
Interest Rs m241102 236.1%   
Profit before tax Rs m2,7036,520 41.5%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m6752,569 26.3%   
Profit after tax Rs m2,0288,961 22.6%  
Gross profit margin %13.923.5 58.9%  
Effective tax rate %25.039.4 63.4%   
Net profit margin %6.325.7 24.6%  
BALANCE SHEET DATA
Current assets Rs m17,34039,932 43.4%   
Current liabilities Rs m9,55916,276 58.7%   
Net working cap to sales %24.267.9 35.7%  
Current ratio x1.82.5 73.9%  
Inventory Days Days10054 187.3%  
Debtors Days Days5786 66.0%  
Net fixed assets Rs m20,77939,101 53.1%   
Share capital Rs m2521,000 25.2%   
"Free" reserves Rs m24,49938,591 63.5%   
Net worth Rs m24,55340,556 60.5%   
Long term debt Rs m3,51720,724 17.0%   
Total assets Rs m39,59584,816 46.7%  
Interest coverage x12.264.9 18.8%   
Debt to equity ratio x0.10.5 28.0%  
Sales to assets ratio x0.80.4 197.3%   
Return on assets %5.710.7 53.6%  
Return on equity %8.322.1 37.4%  
Return on capital %10.519.0 55.3%  
Exports to sales %48.630.7 158.2%   
Imports to sales %14.220.4 69.8%   
Exports (fob) Rs m15,61710,717 145.7%   
Imports (cif) Rs m4,5717,105 64.3%   
Fx inflow Rs m15,61711,789 132.5%   
Fx outflow Rs m5,8288,393 69.4%   
Net fx Rs m9,7903,396 288.3%   
CASH FLOW
From Operations Rs m2,7645,264 52.5%  
From Investments Rs m-1,432-9,540 15.0%  
From Financial Activity Rs m-1,59110,867 -14.6%  
Net Cashflow Rs m-2596,591 -3.9%  

Share Holding

Indian Promoters % 45.9 40.4 113.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.4 8.4 135.7%  
FIIs % 25.3 10.7 236.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 19.9 87.4%  
Shareholders   36,892 109,995 33.5%  
Pledged promoter(s) holding % 2.1 0.0 5,350.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  MERCK LTD  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 16, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS